Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Voorraadrapport

Marktkapitalisatie: US$2.1b

Mirum Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Mirum Pharmaceuticals is Chris Peetz, benoemd in Mar2019, heeft een ambtstermijn van 5.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.45M, bestaande uit 10.2% salaris en 89.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.6% van de aandelen van het bedrijf, ter waarde $ 12.55M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 4.3 jaar.

Belangrijke informatie

Chris Peetz

Algemeen directeur

US$6.5m

Totale compensatie

Percentage CEO-salaris10.2%
Dienstverband CEO5.7yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijn3.7yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Nov 15
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Nov 03
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Oct 04

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 17

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Jul 13
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

Analyse CEO-vergoeding

Hoe is Chris Peetz's beloning veranderd ten opzichte van Mirum Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$109m

Mar 31 2024n/an/a

-US$159m

Dec 31 2023US$6mUS$660k

-US$163m

Sep 30 2023n/an/a

-US$164m

Jun 30 2023n/an/a

-US$176m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$4mUS$624k

-US$136m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$53m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$4mUS$600k

-US$84m

Sep 30 2021n/an/a

-US$179m

Jun 30 2021n/an/a

-US$153m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$3mUS$512k

-US$103m

Sep 30 2020n/an/a

-US$84m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$6mUS$458k

-US$53m

Sep 30 2019n/an/a

-US$61m

Dec 31 2018US$385kUS$32k

-US$26m

Compensatie versus markt: De totale vergoeding ($USD 6.45M ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.37M ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Peetz (45 yo)

5.7yrs

Tenure

US$6,451,720

Compensatie

Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christopher Peetz
CEO & Director5.7yrsUS$6.45m0.60%
$ 12.6m
Peter Radovich
COO & President4.6yrsUS$2.37m0.042%
$ 870.0k
Eric Bjerkholt
Chief Financial Officer1.2yrsUS$4.69m0.069%
$ 1.4m
Pamela Vig
Chief Scientific Officerless than a yearUS$1.51m0.19%
$ 4.0m
Andrew McKibben
Vice President of Investor Relations and Financeno datageen gegevensgeen gegevens
Paul Ross
Chief Compliance Officer4.6yrsgeen gegevensgeen gegevens
Erin Campany
Senior Vice President of Human Resources5.8yrsgeen gegevensgeen gegevens
Lara Longpre
Chief Development Officer5.9yrsUS$1.51m0.20%
$ 4.1m
Vinita Kumar
Senior vice President of Quality2.8yrsgeen gegevensgeen gegevens
Jean-Luc Girardet
Senior Vice President of Technical Operations1.8yrsgeen gegevensgeen gegevens
Joanne M. Quan
Chief Medical Officerless than a yeargeen gegevens0.00025%
$ 5.2k
Jolanda Howe
Senior VP & Global Controllerno datageen gegevens0.0050%
$ 105.4k

3.7yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MIRM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Christopher Peetz
CEO & Directorno dataUS$6.45m0.60%
$ 12.6m
Patrick Heron
Independent Director6yrsUS$401.75k0%
$ 0
Laura Brege
Independent Director5.3yrsUS$426.75k0.021%
$ 434.8k
Michael Grey
Independent Non-Executive Chairman of the Board5.7yrsUS$451.75k0.58%
$ 12.2m
Laurent Fischer
Independent Director5.4yrsUS$421.75k0.014%
$ 293.5k
Timothy Walbert
Independent Director1.6yrsUS$671.53k0%
$ 0
Sona Saira Ramasastry
Independent Director2.4yrsUS$411.75kgeen gegevens
William Fairey
Independent Director3.3yrsUS$411.75k0%
$ 0
Lon Cardon
Independent Director2yrsUS$194.47k0%
$ 0

4.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MIRM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).